ClinicalTrials.gg
RecruitingNCT07435038Updated Sep 18, 2026

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

A Phase 1/2 interventional study of BPI-572270 in Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by Betta Pharmaceuticals Co., Ltd.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Betta Pharmaceuticals Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Carcinoma, Non-Small-Cell Lung by Betta Pharmaceuticals Co., Ltd. — 10 open to participants now, 13 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · Betta Pharmaceuticals Co., Ltd..

Planned enrollment
17th of 43
120 · median 90
Started
2026
with 2 others
Phase 1/2
6 of 45
3 open now
Primary completion
2028-12
later than 12 of 12 live
Registered
44th of 45
by date

Among the 45 studies in Carcinoma, Non-Small-Cell Lung by Betta Pharmaceuticals Co., Ltd., this one is the 17th largest by planned enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 1/2, reaches primary completion later than 12 of the 12 other live ones, and was the 44th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 45 studies in Carcinoma, Non-Small-Cell Lung by Betta Pharmaceuticals Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Carcinoma, Non-Small-Cell Lung by Betta Pharmaceuticals Co., Ltd., or all of them as a file.
02

Study summary

Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.

Read the detailed description

This is a Phase 1/2, multicenter open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and clinical activity of escalating doses of BPI-572270 in adult patients with advanced solid tumors harboring specific RAS mutations, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose [RP2D] within investigated patient population groups, and to further expand the enrollment of more patients to evaluate the efficacy endpoints (ORR/DCR/DOR/TTR).

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Advanced Solid Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing.
  • Have received prior standard therapy appropriate for tumor type and stage.
  • Have (ECOG) performance status of 0 or 1 Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Primary central nervous system (CNS) tumors active and untreated .
  • Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication.
  • History of any other unstable or concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Study BPI-572270 in adults with specific RAS mutant advanced solid tumors

    Capsules; Administer once a day on an empty stomach.

    Drug: BPI-572270

Interventions

  • DrugBPI-572270

    Oral Tablets

    Also known as: BPI-572270 Capsule

06

What researchers measure

Primary outcomes

  1. DLT

    Number of Participants with Dose-Limiting Toxicity (DLT)AEs, including incidence and severity of findings in laboratory values and vital signs

    Time frame: up to 2 tears

  2. RP2D

    Determination of RP2D in the expansion phase

    Time frame: up to 2 tears

  3. ORR

    Further expand the inclusion to clarify the efficacy endpoint ORR

    Time frame: up to 3 tears

Secondary outcomes

  1. Cmax

    Maximum Observed Blood Concentration (Cmax) of BPI-572270

    Time frame: up to 15 weeks

  2. AUC

    Area Under Blood Concentration Time Curve (AUC) of BPI-572270

    Time frame: up to 15 weeks

  3. Disease Control Rate (DCR)

    Time frame: up to 3 years

07

Study locations

1 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 34 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Feb 27, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Dec 28, 2028
CompletionEst.
Oct 28, 2029
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07435038
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Jan 29, 2026
Primary completion
Dec 28, 2028 (estimated)
Completion
Oct 28, 2029 (estimated)
Last update
Sep 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion